natures semaglutide Redefining peptide therapeutics with Oral Semaglutide for Weight Loss
Description
Intrahepatic fat, not visceral fat, is linked with metabolic complications of obesity
As a GLP-1, GIP, and glucagon receptor agonist being evaluated for obesity and type 2 diabetes, retatrutide shares some skin-related adverse effects with other subcutaneous incretin therapies, whilst its full dermatological profile remains under investigation
Therefore, an anti-mouse GIPR surrogate antibody was used to conjugate with the GLP-1 analogue peptide to generate an AMG 133 murine surrogate to assess its effect in pharmacology studies in mice
Had all questions addressed and answered
You can learn more in our guide to the differences between Wegovy and Saxenda
